Coronavirus | Serum Institute says reports of Covishield vaccine availability in 73 days false

It would be commercialised once the trials are proven successful , it says.

Updated - August 23, 2020 11:42 pm IST

Published - August 23, 2020 10:23 pm IST - Pune

A research scientist works inside a laboratory of Serum Institute of India, in Pune. File

A research scientist works inside a laboratory of Serum Institute of India, in Pune. File

The city-based Serum Institute of India (SII) on Sunday clarified that claims in the media regarding its COVID-19 vaccine Covishield’s availability in 73 days are completely ‘false’ and ‘conjectural’.

Full coverage on coronavirus

There were reports in certain sections in the media claiming that the SII would be able to commercialise its vaccine, which is being developed by AstraZeneca and Oxford University, in the next 73 days.

“The SII would like to clarify that the current claims surrounding Covishield’s availability in the media are completely false and conjectural. Presently, the government has granted us permission to only manufacture the vaccine and stockpile it for future use,” read a statement issued by the company.

It said the Covishield would be commercialised once the trials were proven successful and all the requisite regulatory approvals were in place.

Also read: If everything goes well India would get COVID-19 vaccine by year-end: Harsh Var dhan

“The phase-3 trials for the Oxford-AstraZeneca vaccine are still under way. And only once the vaccine is proven immunogenic and efficacious, SII will confirm its availability, officially,” it said.

With the trials of the Covishield vaccine showing encouraging results, Adar Poonawalla, CEO of the Serum Institute of India (SII), had earlier said at least 300 million doses would be ready by December.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.